Compare Norfolk Southern Corporation (NSC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Repligen Corporation Common Stock — how do they compare? Norfolk Southern Corporation trades at $326.37 (market cap $72.13B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Norfolk Southern Corporation is far larger — about 6.5× Repligen Corporation Common Stock's market cap, and Norfolk Southern Corporation pays a 1.68% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 34 Days and Repligen Corporation Common Stock for 0 Days on average.
| NSC | RGEN | |
|---|---|---|
Market Cap | $72.13B | $11.14B |
Volume | 650,750 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $352.98 | $194.57 |
52-Week Low | $278.19 | $102.87 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $87.68B | $11.02B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $321.14, up 0.56% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (21.02% net margin). Recent news highlights momentum for the Union Pacific merger, while institutional buying and a $361.86 consensus price target suggest upside potential.
Outlook remains positive with merger progress and dividend stability, but risks include fuel cost pressures and regulatory hurdles. The current valuation (P/E 27.4) demands execution on freight share gains and merger benefits to justify further gains.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
